Clinical Trial Update: A Study To Assess The Effects Of A Single Dose Of GSK598809 In Modulating Nicotine Reward [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating a single dose of GSK598809 for modulating nicotine reward; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nicotine Dependence

Drugs mentioned

• GSK598809 (GSK598809)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Substance Dependence | Phase 1 | Status: COMPLETED